GOLDAN KEITH A. (Chief Financial Officer) sold 1.4% of their position (2.08K shares) of SYNDAX PHARMACEUTICALS INC on the open market
Open‑market sale worth $42.9K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/6/2026ACC: 0001193125-26-041497
Officer· Chief Financial Officer
Since Jun 2022
+169.39K
Net shares
Net buyer
$42.9K
Total sold
1
Open market trades
0B · 1S
5
Total transactions
171.47K acquired · 2.08K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+1.22K
Price / share
$8.48
Trade value
$10.34K
% of position
1.3%
1/30/2026
92.45K→93.67K
Common Stock
Direct
Shares
+21.50K
Price / share
—
Trade value
—
% of position
23.0%
2/4/2026
93.67K→115.17K
Common Stock
Direct
Shares
+30.75K
Price / share
—
Trade value
—
% of position
26.7%
2/4/2026
115.17K→145.92K
Common Stock
Direct
Shares
−2.08K
Price / share
$20.62
Trade value
$42.93K
% of position
1.4%
2/6/2026
145.92K→143.84K
Total
Net shares
+51.39K
Net value
-$32.59K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/30/2026 | J · J | +1.22K | $8.48 | $10.34K | 1.3% | 92.45K | 93.67K |
| Common Stock Direct | 2/4/2026 | A · Award | +21.50K | — | — | 23.0% | 93.67K | 115.17K |
| Common Stock Direct | 2/4/2026 | A · Award | +30.75K | — | — | 26.7% | 115.17K | 145.92K |
| Common Stock Direct | 2/6/2026 | S · Sale | −2.08K | $20.62 | $42.93K | 1.4% | 145.92K | 143.84K |
| Total | +51.39K | -$32.59K | ||||||
Derivative Transactions1
Stock Options (Right to buy)
Direct
Converts to
Common Stock
118K shares
Shares
+118K
Strike price
20.43
Held after
118K
Exercisable
—
2/4/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy) Direct | Common Stock118K shares | 2/4/2026 | A · Award | +118K | 20.43 | — | 118K |